Macular telangiectasia type 2: clinical case report
Medical Review (Med. pregled), 2025, 61(3), 43-47.
N. Dzhemal1, G. Markov3, V. Haykin1,2, Y. Zdravkov1,2, A. Oscar1,2
1 Eye Clinic, University Нospital Alexandrovska – Sofia
2 Department of Ophthalmology, Medical University – Sofia
3 Medical Center Gina – Sofia
Abstract. Macular telangiectasia, also known as “idiopathic juxtafoveоlar retinal telangiecta¬sia“, involves telangiectatic changes in the macular capillary network. The most common variant is macular telangiectasia type 2. This is a rare, acquired disease that affects both eyes asymmetrically, with a gradually progressive course, with deterioration of central vision, affecting adults over 40 years of age, and with a predominance of the female sex. We present a clinical case of macular telangiectasia type 2 in a 44-year-old woman with noninsulin-dependent diabetes mellitus (NIDDM), who complained of decreased vision in the right eye and metamorphopsia of both eyes. At the Clinic for Eye Diseases of University Hospital „Aleksandrovska“ she underwent a complete ophthalmological examination and a number of highly specialized apparatus examinations such as optical coherence tomography (OCT), angio-OCT, fluorescein angiography (FA) and fundus autofluorescence. The patient was treated with intravitreal applications of the anti-VEGF drug – аflibercept, in both eyes, after which a significant improvement in visual acuity was observed. Treatment with intravitreal applications of anti-VEGF drugs in the proliferative phase is considered a first-line strategy in the treatment of this condition, as it does give promising results for the control of the retinal changes.
Key words: macular telangiectasia type 2, retina, vascular endothelial growth factor